IP Library Patent Application 15115750
Patent Application
App. No. 15/115,750

DETECTION, MONITORING AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/115,750
Abstract

Detection, monitoring and treatment of acute myocardial infarction (AMI) using a hybrid immunoassay to both Lp-PLA2 and ApoA1. Described herein are assays and method of performing them useful for the detection of AMI. Also described are methods of monitoring a patient at risk for, or suffering from, AMI. Also described herein are methods and assays for treating patient having or at risk of suffering from AMI.

Claims (34)

1 . A method of treating, detecting or monitoring acute myocardial infarction (AMI) comprising:

exposing a blood sample from a patient to a solid phase support onto which an Lp-PLA2-binding molecule is coupled;

incubating the blood sample with an ApoA1-binding molecule; and

detecting the level of ApoA1 from the solid phase.

2 . A method of treating, detecting or monitoring acute myocardial infarction (AMI) comprising:

exposing a blood sample from a patient to a solid phase support onto which an Lp-PLA2-binding molecule is coupled;

incubating the solid phase support with an ApoA1-binding molecule;

washing the solid phase support;

detecting the level of ApoA1 from the solid phase; and

treating the patient for AMI if the amount of ApoA1 detected is below a threshold.

3 . The method of claim 1 , further comprising treating the patient for AMI if the level of ApoA1 is below a threshold.

4 . The method of claim 1 , further comprising treating the patient for AMI if the level of ApoA1 detected is below 0.7 ng/ml.

5 . The method of claim 1 , further comprising washing the solid phase support.

6 . The method of claim 1 , wherein exposing the blood sample from the patient to the solid phase support comprising adding the sample to a solid phase support to which an antibody or an antibody fragment specific for Lp-PLA2 is coupled.

7 . The method of claim 1 , wherein incubating the blood sample with the ApoA1-binding molecule comprises incubating with an antibody or an antibody fragment that binds ApoA1.

8 . The method of claim 1 , wherein detecting the level of ApoA1 from the solid phase support comprises reacting a horseradish peroxidase (HRP) bound to an antibody against ApoA1 to detect a signal and quantifying the detected signal.

9 . A system for detecting or monitoring acute myocardial infarction (AMI), the system comprising:

a first component comprising an Lp-PLA2 binding molecule coupled to a solid-phase support;

a reagent comprising an ApoA1 binding molecule to which a detection moiety is coupled.

10 . The system of claim 9 , wherein the first component comprises a solid-phase support to which an antibody or antibody fragment that binds to Lp-PLA2 has been coupled.

11 . The system of claim 9 , wherein the reagent comprises a solution including an ApoA1 antibody or antibody fragment coupled to a detection moiety.

12 . The system of claim 9 , further comprising a set of standards configured to calibrate the level of ApoA1 detected by the detection moiety.

13 . A system for detecting or monitoring acute myocardial infarction (AMI), the system comprising:

a first component comprising an LpPLA2 binding molecule coupled to a solid-phase support;

a first wash buffer;

a reagent comprising an ApoA1 binding molecule to which a detection moiety is coupled; and

a detection buffer.

14 . The system of claim 13 , wherein the first component comprises a solid-phase support to which an antibody or antibody fragment that binds to Lp-PLA2 has been coupled.

15 . The system of claim 13 , wherein the reagent comprises a solution including an ApoA1 antibody or antibody fragment coupled to a detection moiety.

16 . The system of claim 13 , further comprising a set of standards configured to calibrate the level of ApoA1 detected by the detection moiety.

17 . The method of claim 2 , further comprising treating the patient for AMI if the level of ApoA1 detected is below 0.7 ng/ml.

18 . The method of claim 2 , wherein exposing the blood sample from the patient to the solid phase support comprising adding the sample to a solid phase support to which an antibody or an antibody fragment specific for Lp-PLA2 is coupled.

19 . The method of claim 2 , wherein incubating the blood sample with the ApoA1-binding molecule comprises incubating with an antibody or an antibody fragment that binds ApoA1.

20 . The method of claim 2 , wherein detecting the level of ApoA1 from the solid phase support comprises reacting a horseradish peroxidase (HRP) bound to an antibody against ApoA1 to detect a signal and quantifying the detected signal.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2017
From: GENERAL ATOMICS
To: DIAZYME LABORATORIES, INC.
Reel/Frame 041651/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2017
From: DIADEXUS, INC.
To: GENERAL ATOMICS
Reel/Frame 041245/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2016
From: ZHUO, SHAOQIU
To: DIADEXUS, INC.
Reel/Frame 040791/0622 →